PersonnelTakeda Pharmaceutical Company Limited: Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 202630-Jan-2025 / 09:31 CET/CESTDisclosure of an inside information acc. to Article 17 ...
Koichi Mamegano, an analyst from Bank of America Securities, maintained the Buy rating on Takeda Pharmaceutical Co (TKPHF – Research Report).
Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...
Zydus Takeda Healthcare Private Limited, a joint venture between Zydus Lifesciences and Takeda Pharmaceutical, celebrates the ...
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda ...
Takeda Pharmaceutical (NYSE:TAK – Get Free Report) is projected to announce its earnings results before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of ...
BusinessWire India Mumbai Vashi Maharashtra [India] January 31 Zydus Takeda Healthcare Private Limited ZTHPL a joint venture company set up by Zydus Lifesciences Limited and Takeda Pharmaceutical Comp ...
Takeda Pharmaceutical named Julie Kim, who heads its U.S. business, as its new chief executive starting in 2026, elevating her to the small but growing ranks of women leading Japanese companies.
Julie Kim, 54, has been running Takeda’s U.S. operations since 2022 and will assume the role of CEO in June next year, ...
The Japanese drugmaker said that Kim, president of its U.S. business unit, will succeed Chief Executive Christophe Weber, who ...
Atomi Financial Group Inc. trimmed its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) by 17.4% during the fourth quarter, according to its most recent 13F filing ...
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers ...